{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.7","upperLimit":"41.1","value":"31.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"}],"units":"Participants"}],"description":"Percentage of participants with clinical remission at Week 6 as assessed by the Mayo score was reported. Clinical remission was defined as a Mayo score of less than or equal to (\\<=) 2 point, with no individual sub-score greater than (\\>) 1. The Mayo score was sum of 4 sub-scores (that is, stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment); each rated on a scale from 0 to 3, with higher scores indicating more severe disease. The total score was calculated as the sum of the 4 sub scores and values ranged from 0 to 12. A score of 3 to 5 points indicated mildly active disease; a score of 6 to 10 indicated moderately active disease; and a score of 11 to 12 indicated severe disease.","dispersionType":"90% Confidence Interval","groups":[{"description":"In short term phase (Week 0-6), participants weighing greater than or equal to (\\>=) 45 kilograms (kg), received fixed subcutaneous induction doses of golimumab 200 milligrams (mg) at Week 0 and 100 mg at Week 2. Participants weighing less than (\\<) 45 kg received body surface area (BSA) adjusted doses with 120 milligrams per square meter (mg/m\\^2) (up to a maximum of 200 mg) at Week 0 and 60 mg/m\\^2 (up to a maximum of 100 mg) at Week 2. In long-term Phase (Week 6 through Week 54), participants who showed a clinical response at Week 6 continued receiving subcutaneous golimumab 100 mg or 60 mg/m\\^2 every 4 weeks (q4w) through Week 50. Participants with no clinical response (non-responders) at Week 6 received additional golimumab doses at Weeks 6 and 10 at the discretion of the investigator. Participants who showed partial Mayo response at Week 14, continued golimumab 100 mg or 60 mg/m\\^2 qw4 through Week 50. Participants without a partial Mayo response at Week 14 were withdrawn from further treatment and entered a 16-week safety follow-up period after the last dose. In study extension (Week 54 to end of study) phase, participants who were benefited from golimumab, at the discretion of the investigator, continued to receive SC golimumab q4w until marketing authorization is obtained for golimumab or participant turns 18 years had access to commercially available golimumab or decided by the sponsor.","id":"OG000","title":"Group 1: Golimumab"}],"paramType":"NUMBER","populationDescription":"FGAS1 included all enrolled participants who received at least 1 dose (complete or partial) of golimumab during the induction phase. This outcome measure was planned to be reported for \"Group 1: Golimumab\" arm only.","reportingStatus":"POSTED","timeFrame":"Week 6","title":"Percentage of Participants With Clinical Remission at Week 6 as Assessed by the Mayo Score","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}